הזרקה אורתוטופית לפד שומן החלב: ביסוס סרטן השד בעכברות

Executive Industry Relevance

Establishing physiologically relevant breast cancer models is critical for preclinical target validation and therapeutic screening. Orthotopic injection into the mammary fat pad enables tumor growth in a native microenvironment, improving predictive confidence in drug efficacy and mechanistic de-risking. This approach supports early discovery workflows by providing a disease-relevant system for evaluating lead compounds and pathway modulation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses in a native tumor microenvironment, supporting biological de-risking of targets.
• Operational Value: Generates reproducible tumor models for consistent pathway interrogation across screening campaigns.
• Strategic Value: Improves target confidence by linking molecular perturbations to phenotypic tumor growth in vivo.

Screening & Assay Development

• Scientific Value: Produces quantifiable tumor growth signals via luciferase expression, enabling longitudinal monitoring of therapeutic response.
• Operational Value: Standardizes cell delivery technique to reduce variability in engraftment efficiency across compound testing.
• Strategic Value: Supports assay readiness for high-throughput in vivo screening by establishing a reliable engraftment workflow.

Translational & Preclinical Research

• Scientific Value: Maintains disease relevance by modeling tumor-stroma interactions in the mammary fat pad, improving translational biomarker alignment.
• Operational Value: Facilitates continuity from target validation to preclinical efficacy studies using the same orthotopic model.
• Strategic Value: Enables risk-adjusted advancement decisions by capturing microenvironment-dependent drug responses.

Pipeline & Workflow Integration

The orthotopic mammary fat pad injection method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, providing a reproducible in vivo readout for therapeutic evaluation.

• Discovery Biology: Supports hypothesis testing by enabling functional validation of oncogenic pathways in a physiologically contextualized tumor model.
• Screening: Delivers standardized tumor engraftment for consistent compound evaluation in vivo, reducing false negatives from variable take rates.
• Analytics: Generates bioluminescent imaging readouts that quantify tumor burden over time, enabling longitudinal pharmacodynamic assessments.
• Translational Research: Connects early target modulation to phenotypic tumor outcomes in a disease-relevant system, supporting biomarker-driven go/no-go decisions.
• Enterprise Reuse: Establishes a reusable engraftment platform applicable across multiple breast cancer cell lines and therapeutic modalities.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by modeling tumor growth in a native stromal context, reducing mechanistic ambiguity in target validation.
• Operational Value: Improves reproducibility through standardized surgical technique and cell preparation protocols.
• Strategic Value: Increases capital efficiency by improving engraftment success rates, reducing animal use per informative data point.
• Portfolio Impact: Enables risk-based prioritization of leads by linking in vivo efficacy to target modulation in a physiologically relevant model.

Implementation Considerations

• Requires expertise in rodent handling, aseptic technique, and microsurgical injection skills.
• Dependent on sterile microsyringes, fine-gauge needles, and bioluminescent imaging infrastructure.
• Necessitates cross-team standardization between animal care, compound delivery, and imaging teams.
• Must account for variability in mammary fat pad anatomy across mouse strains and ages.
• Limited by technical skill dependency; improper injection can result in ectopic engraftment or failed tumor take.

Biopharma FAQs